COMP <GO>
AGIO vs GENB // 10Y YIELD & FRED MACRO BETA
Agios Pharmaceuticals Inc. (NASDAQ) VS. Generate Biomedicines Inc. (NASDAQ) • 15-METRIC TALLY: AGIO 0
— GENB 2
■ METRIC PARITY
LAST: $29.95 (-1.96%) • MKT CAP: $1.82B
macro-sensitivity
—
LAST: $13.21 (-8.64%) • MKT CAP: $1.86B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGIO VS. GENB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGIO | GENB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -33.80% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -16.97% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 48.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.84 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.5 | 51.6 | -9.10 | GENB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.82B | $1.86B | -$32.1M | GENB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGIO REV | GENB REV | AGIO GROSS % | GENB GROSS % | AGIO FCF | GENB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $54.0M | $138.7M | 88.3% | — | -$377.3M | — |
| FY 2024 | $36.5M | — | 88.6% | — | -$391.5M | — |
| FY 2023 | $26.8M | — | — | — | -$296.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGIO // BETA —
GENB // BETA —